TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females age 18-70 years~* Type 2 diabetes mellitus for ≥ 6 months prior to Screening Visit 1~* On a stable (\> 3 months prior to Screening Visit 1) treatment regimen of metformin monotherapy;~* Fasting plasma glucose \< 240 mg/dL at Screening Visit 1~* HbA1c ≥ 7% and ≤ 10% at Screening Visit 1~Exclusion Criteria:~* Prior treatment with exenatide~* Treatment with any of the following antidiabetic agents within 3 months prior to Screening Visit 1: TZDs, sulfonylureas, DPP IV inhibitors, acarbose, or insulin (injected or inhaled)~* History of type 1 diabetes and/or history of diabetic ketoacidosis~* Body mass index ≥ 40 kg/m2;~* History of organ transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ITCA 650 20 mcg/day (Type: EXPERIMENTAL): None
- ITCA 650 40 mcg/day (Type: EXPERIMENTAL): None
- Exenatide Injection (Type: ACTIVE_COMPARATOR): None
- ITCA 650 20/20 (Type: EXPERIMENTAL): None
- ITCA 650 20/60 (Type: EXPERIMENTAL): None
- ITCA 650 40/40 (Type: EXPERIMENTAL): None
- ITCA 650 40/80 (Type: EXPERIMENTAL): None
- Ex Inj/ITCA 650 40 (Type: EXPERIMENTAL): None
- Ex Inj/ITCA 650 60 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mechanisms of Manual Therapies in CAI Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~Individuals with Chronic Ankle Instability which will be defined as those individuals who:~* have sustained at least two lateral ankle sprains;~* have experienced at least one episode of giving way within the past 6-months;~* answer 4 or more questions of yes on the Ankle Instability Instrument;~* have self-assessed disability scores of ≤90% on the Foot and Ankle Ability Measure;~* have self-assessed disability scores ≤80% on the Foot and Ankle Ability Measure-Sport.~Exclusion criteria for Chronic Ankle Instability will include:~* known vestibular and vision problems,~* acute lower extremities and head injuries (\<6 weeks),~* chronic musculoskeletal conditions known to affect balance (e.g., Anterior Cruciate Ligament deficiency) and~* a history of ankle surgeries to fix internal derangement.~Participants will also be excluded if they have any of the following which are contraindications to Transcranial Magnetic Stimulation testing:~* metal anywhere in the head (except in the mouth),~* pacemakers,~* implantable medical pumps,~* ventriculo-peritoneal shunts,~* intracardiac lines,~* history of seizures,~* history of stroke~* history of serious head trauma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Control group that will receive no intervention throughout the duration of the study (2-weeks).
- Joint Mobilization (Type: EXPERIMENTAL): Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of Grade III anterior-to-posterior talocrural joint mobilization with 1-minute between sets. Mobilizations will be large-amplitude, 1-s rhythmic oscillations from the mid- to end range of arthrokinematic motion.
- Massage (Type: EXPERIMENTAL): Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of plantar massage bouts with 1-minute between sets. The massage will be a combination of petrissage and effleurage to the entire plantar surface.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Examining Community-based Effectiveness of a Substance Use and HIV Risk Reduction Intervention for Young Men of Color

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-negative test result from the past 90 days~* 15-29 years of age~* Born biologically male or currently identifying as male~* Sex with men in the past 90 days~* ≥ 5 days of illicit drug use in the past 90 days~* ≥ 1 episode of condomless anal sex (CAS) in the past 90 days, or a positive sexually transmitted infection test result in the past 90 days.~* Living in the New York City area~* Able to communicate in English~Exclusion Criteria:~* Serious cognitive or psychiatric impairments~* ≥5 days of injection drug use in the past 90 days~* Currently taking Truvada as Pre-Exposure Prophylaxis (PrEP)

- Gender: MALE
- Minimum Age: 15 Years
- Maximum Age: 29 Years
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: OTHER): The YMHP intervention is a 4 session Motivational Interviewing (MI) intervention. In session 1, youth will choose which behavior to discuss first (substance use or sexual risk behavior), and the Health Educator counselor will elicit the client's view of the problem using standard MI techniques, building motivation for change by eliciting and reinforcing change talk, and clarifying the youth's own personal goals for maintaining their sexual health/considering changes in their substance use. The second session follows the same format for the second target behavior. In the subsequent two sessions, the counselor will discuss Pre-exposure Prophylaxis (PrEP) uptake as part of a change plan, continue to elicit and reinforce change talk, problem-solve barriers, consolidate commitment, and consider strategies to maintain behavior change.
- Enhanced Treatment as Usual (Type: OTHER): The Enhanced Treatment as Usual arm involves referring youth to standard of care services available at the community based organization for substance use and sexual health. This includes available services for Pre-exposure prophylaxis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Investigation of the WaveLight® EX500 Excimer Laser

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Intended to treat bilaterally;~* Hyperopia with or without astigmatism as specified in the protocol;~* Stable vision as specified in the protocol;~* Other protocol-defined inclusion criteria may apply.~Key Exclusion Criteria:~* Glaucoma;~* Cataracts;~* Previous eye surgery;~* Intent to have monovision treatment;~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- WaveLight EX500 excimer laser system (Type: EXPERIMENTAL): Laser-assisted in situ keratomileusis (LASIK) surgery using the WaveLight EX500 excimer laser system

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pre- and newly postmenopausal (up to 8 years) women ages 18 and older~* Breast cancer treated with chemotherapeutic agents, with or without tamoxifen/aromatase inhibitors~* Negative pregnancy test~Exclusion Criteria:~* Stage 4 breast cancer~* Any illness or medications known to affect bone metabolism~* History of osteoporosis or history of vertebral or hip fractures~* Kidney stones in the past 5 years~* Active peptic ulcer disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: PLACEBO_COMPARATOR): Group A will receive active study drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, aged 18\~75 years old;~* Confirmed T2DM patients meet the diagnostic criteria for type 2 diabetes published by WHO1999；~* 18.5 kg/m2 \< BMI \< 40.0 kg/m2 at screening;~* 7.5% ≤ HbA1c ≤ 11.0% at screening;~* 7.0% ≤ HbA1c ≤ 10.5% when the random;~* 18.5 kg/m2 \< BMI \< 40.0 kg/m2 during screening and before randomization~Exclusion Criteria:~* T1DM;~* Continuous use of insulin for more than 14 days within 1 year before screening or before randomization；~* Treatment with any dipeptidylpeptidase 4 (DPP-4) inhibitor or glucose-dependent insulin-stimulating peptide (GIP) or/and glucagon-like peptide-1 (GLP-1) receptor agonist prior to screening or randomized prior treatment；~* Screening for any of the following heart diseases within the first 6 months or before randomization；~* Patients whose hypertension was not effectively controlled during screening or before randomization (after resting ≥5 minutes, systolic blood pressure ≥160mmHg and/or diastolic blood pressure ≥100mmHg)；~* Serum amylase or lipase \>3×ULN or those with previous diagnosis of acute/chronic pancreatitis were screened or randomly screened；~* Screening for severe trauma or infection that may affect glycemic control within the first month or before randomization；~* A history or family history of medullary thyroid carcinoma (MTC) or multiple endocrine adenomatosis type 2 (MEN2)；~* Known to be allergic or intolerant to the study drug or metformin；~* Female subjects during pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PB-119 once-weekly-subcutaneous injection (Type: EXPERIMENTAL): PB119 (polyethylene glycol exenatide) is a long-acting GLP-1RA for injection, which will be administered 150μg once-weekly subcutaneously to patients in active drug group for 24 weeks.
- Placebo once-weekly-subcutaneous injection (Type: PLACEBO_COMPARATOR): PB-119 150μg matched placebo which will be used in placebo group for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Primary Care Intervention Strategy for Anxiety Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* MINI diagnosed Anxiety Disorder (PTSD, GAD, SAD, PD)~* Speak English or Spanish (English only at UAMS site)~Exclusion Criteria:~* Diagnosis of Bipolar 1~* Drug and alcohol dependence; or abuse of any substance other than marijuana and alcohol~* Acute suicidality or homicidality~Eligible subjects must be current patients at one of the participating primary care clinics which include:~University of Washington:~* Harborview's Adult Medicine Clinic~* Harborview's Family Medicine Clinic~* UWMC's General Internal Medicine Clinic at Roosevelt Clinic~* PSNHC's 45th Street Clinic~* Country Doctor Community Clinic~* Carolyn Downs Family Medical Center~UCLA:~* Desert Medical Group, Palm Springs CA~* High Desert Medical Group, Lancaster, CA~UCSD:~* Kaiser Permanente, Bonita Medical Offices~* Kaiser Permanente, Otay Mesa Outpatient Medical Center~* UCSD Medical Center, Scripps Ranch Medical Office~* UCSD Medical Center, Fourth and Lewis Medical Office~* UCSD Medical Center, Perlman Ambulatory Care Center~* Sharp Rees-Stealy Medical Group, El Cajon~* Sharp Rees-Stealy Medical Group, Mira Mesa~UAMS:~* UAMS UPMG~* Little Rock Diagnostic Clinic~* St. Vincent's Family Clinic South

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CALM Intervention (Type: EXPERIMENTAL): Participant choice of:~Cognitive Behavioral Therapy (CBT) Psychotropic (anti-anxiety) medication optimization
- Treatment as Usual (TAU) (Type: ACTIVE_COMPARATOR): Participants assigned to TAU with their primary care provider (PCP)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Nalmefene in Patients With Alcohol Dependence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~In- and outpatients who:~* had a primary diagnosis of alcohol dependence according to Diagnostic and Statistical Manual of Mental Disorders - text revision (DSM-IV-TR) criteria~* had had ≥6 Heavy Drinking Days (HDDs) in the 4 weeks preceding the Screening Visit~Exclusion Criteria:~The patient:~* had a severe psychiatric disorder or an antisocial personality disorder~* had risk of suicide evaluated by the suicidality module of the Mini-International Neuropsychiatric Interview (MINI)~* had a history of delirium tremens or alcohol withdrawal seizures~* reported current or recent (within 3 months preceding screening) treatment with disulfiram, acamprosate, topiramate, naltrexone or carbimide, or with any opioid antagonists~* was pregnant or breast-feeding~Other protocol-defined inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Nalmefene (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/= 18 years of age~* Rheumatoid arthritis diagnosed according to American College of Rheumatology (ACR) criteria~* Initiated on RoActemra/Actemra treatment according to the Summary of Product Characteristics not more than 6 months before opening of study center~Exclusion Criteria:~* Current serious infection~* Hypersensitivity to the active component or any of the excipients~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab (Type: None): Participants with moderate to severe Rheumatoid arthritis (RA) who had received RoActemra \[Tocilizumab (TCZ)\] treatment for 6 months prior to initiation of study and are inadequate responders to Disease Modifying Anti-Rheumatic Drugs (DMARDs) and anti-Tumor Necrosis Factors (anti-TNFs) agents were observed. Participants received treatment with TCZ with dose of 8 milligrams per kilogram (mg/kg) body weight, intravenously once every 4 weeks for 12 months according to European Union (EU) approved dosage, and Summary of Product Characteristics (SmPC).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prasugrel Re-load Strategies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with angiographically documented coronary artery disease.~2. Age between 18 to 74 years~3. On treatment with prasugrel 10mg/daily for at least 14 days.~Exclusion Criteria:~1. Blood dyscrasias or bleeding diathesis~2. Antiplatelet treatment with clopidogrel or ticlopidine~3. Recent antiplatelet treatment (\< 14 days) with a glycoprotein IIb/IIIa antagonist~4. Platelet count \<100x106/µL~5. Active bleeding or hemodynamic instability.~6. Unstable angina, acute or recent (\<14 days) myocardial infarction.~7. Serum creatinine \>2 mg/dL~8. Baseline ALT \>2.5 times the upper limit of normal~9. Oral anticoagulation with a coumarin derivative~10. History of stroke, TIA or intracranial bleeding~11. Weight \<60kg~12. Pregnant females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel 60mg (Type: ACTIVE_COMPARATOR): Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
- Prasugrel 30mg (Type: ACTIVE_COMPARATOR): Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
- Prasugrel 10mg (Type: NO_INTERVENTION): Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have presumed resectable or partially resectable malignant glioma based on clinical and radiologic evaluation (pathologic confirmation of malignant glioma must be made at the time of surgery if not previously determined). Patients who have previously received CAN-2409 + prodrug on this study may receive an additional CAN-2409 + prodrug course at recurrence if eligibility criteria are still met.~* Tumor must be accessible for injection and must not be located in the brainstem, midbrain, contained within the ventricular system, or located in an infratentorial location.~* Upfront patients must be planning to undergo standard radiation therapy.~* Patients must be 18 years of age or older.~* Performance status must be KPS ≥70.~* Patients must have SGOT (AST) \< 3x upper limit of normal.~* Patients must have serum creatinine \< 2mg/dl and calculated creatinine clearance \>10ml/min.~* Patients must have platelets \> 100,000/mm3 and WBC \> 3000/mm3.~* Patients of reproductive age must agree to use a medically accepted form of birth control while on the study.~* Patients must give study specific informed consent prior to enrollment. For re-administration, patients must be re-consented.~* Patients must be able to tolerate MRI scan procedure~Exclusion Criteria:~* Active liver disease including cirrhosis or hepatitis~* Patients on immunosuppressive drugs (with exception of corticosteroid)~* Known HIV+ patients.~* Patients with acute infections (viral, bacterial or fungal infections requiring therapy).~* Pregnant or breast feeding patients. Female patients of childbearing age must have negative serum or urine pregnancy test within 1 week of beginning therapy.~* Evidence of metastatic disease or other malignancy (except squamous or basal cell skin cancers).~* Other serious co-morbid illness or compromised organ function.~* Patients may not receive chemotherapy until valacyclovir is completed and may not receive other investigational anti-tumor agents within 30 days prior to study entry or during active participation in the study (defined as from CAN-2409 injection until tumor progression).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm (Type: EXPERIMENTAL): This study is an extension of evaluation of the surgical resection arm, Arm B, from a phase Ib study in which dose escalation on arm B was completed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Who Participated in the Study GBT440-001

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects with SCD aged 18 to 60 years inclusive and \>50 kg who have participated in the GBT440-001 study.~2. Subjects, who if female and of child bearing potential, agree to continue to use highly effective methods of contraception prior to enrollment in this study and for 3 months after the last dose of study drug.~3. Subjects, who if male are willing to continue to use barrier methods of contraception, prior to enrollment in this study to 3 months after the last dose of study drug.~Exclusion Criteria:~1. Subjects requiring chronic transfusion therapy.~2. Subjects receiving a blood transfusion within 30 days of enrollment in this study.~3. Female subjects who are pregnant, trying to become pregnant or lactating.~4. Subjects who have a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders, or additional risk factors for torsades de pointe (e.g., heart failure, hypokalemia, personal or family history of long QTc interval).~5. Subjects who have a significant infection or known inflammatory process on admission to this study.~6. Subjects who have acute gastrointestinal symptoms at the time of admission (e.g. nausea, vomiting, diarrhoea, heartburn).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): Single Arm / open label

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete